Weight-loss drugmakers bet billions on boosting supplies

There is a gush of investment from drugmakers Eli Lilly and Novo Nordisk as the companies hasten to boost production of their new anti-obesity drugs. Demand for these drugs, which mimic the natural hormone glucagon-like peptide 1 (GLP-1), has rapidly outstripped supply and the leading duo are now trying to keep pace with the predicted market growth for these incredibly valuable drugs.